Responding more frequently to MiniMed Smart MDI alerts linked to better glucose outcomes for people with diabetes
MiniMed presented new clinical evidence at the 62nd EASD Annual Meeting showing Smart MDI users who responded more frequently to alerts achieved 8.1 percentage points more Time in Range and 0.6 percentage points lower HbA1c. The six-month randomized controlled trial enrolled 143 people with type 1 diabetes and HbA1c above 8%; a separate real-world analysis of more than 5,500 users found a 9.4 percentage-point TIR difference between high and low responders.
Key figures
- Drug Name
- MiniMed Smart MDI system (MiniMed Go / InPen)
- Phase Of Trial
- six-month randomized controlled trial
- Trial participants
- 143
- Alert response threshold
- ≥28%
- Real world users analyzed
- 5500
- Tir gain percentage points
- 8.1
- Hba1c reduction percentage points
- 0.6
- Real world tir difference percentage points
- 9.4
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.